Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
2.

A Bayesian Network risk model for assessing oil spill recovery effectiveness in the ice-covered Northern Baltic Sea.

Lu L, Goerlandt F, Valdez Banda OA, Kujala P, Höglund A, Arneborg L.

Mar Pollut Bull. 2019 Feb;139:440-458. doi: 10.1016/j.marpolbul.2018.12.018. Epub 2019 Jan 22.

3.

Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.

Lindberg A, Talala K, Kujala P, Stenman UH, Taari K, Kilpeläinen TP, Tammela TL, Auvinen A.

Int J Cancer. 2019 Aug 1;145(3):632-638. doi: 10.1002/ijc.32129. Epub 2019 Feb 4.

PMID:
30653262
4.

Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.

Veijalainen O, Kares S, Kujala P, Vuento R, Osuala V, Tirkkonen M, Luukkaala T, Kholová I, Mäenpää J.

Cytopathology. 2019 Mar;30(2):150-156. doi: 10.1111/cyt.12652. Epub 2018 Dec 6.

PMID:
30421573
5.

Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.

Rantaniemi L, Tammela TLJ, Kujala P, Murtola TJ.

Scand J Urol. 2018 Aug;52(4):269-276. doi: 10.1080/21681805.2018.1492967. Epub 2018 Oct 26.

PMID:
30362865
6.

The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).

Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P, Stenman UH, Tammela TLJ, Auvinen A.

Clin Cancer Res. 2019 Jan 15;25(2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. Epub 2018 Oct 15.

PMID:
30322875
7.

Purity and mechanical strength of naturally frozen ice in wastewater basins.

John M, Suominen M, Sormunen OV, Hasan M, Kurvinen E, Kujala P, Mikkola A, Louhi-Kultanen M.

Water Res. 2018 Nov 15;145:418-428. doi: 10.1016/j.watres.2018.08.063. Epub 2018 Aug 29.

PMID:
30176505
8.

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Murtola TJ, Syvälä H, Tolonen T, Helminen M, Riikonen J, Koskimäki J, Pakarainen T, Kaipia A, Isotalo T, Kujala P, Tammela TLJ.

Eur Urol. 2018 Dec;74(6):697-701. doi: 10.1016/j.eururo.2018.06.037. Epub 2018 Jul 18.

PMID:
30031572
9.

Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease.

Tolonen TT, Riikonen J, Tammela TLJ, Koivusalo L, Haapasalo H, Kujala P, Kaipia A.

Ann Diagn Pathol. 2018 Aug;35:80-84. doi: 10.1016/j.anndiagpath.2018.06.001. Epub 2018 Jun 5. No abstract available.

PMID:
29886397
10.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2017 Nov 11. pii: S2405-4569(17)30258-4. doi: 10.1016/j.euf.2017.11.002. [Epub ahead of print]

11.

Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies.

Koivusalo L, Kaipia A, Kujala P, Isola J, Tolonen TT.

Histol Histopathol. 2018 Apr;33(4):399-405. doi: 10.14670/HH-11-940. Epub 2017 Oct 23.

PMID:
29058306
12.

Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS.

Am J Surg Pathol. 2018 Jan;42(1):103-115. doi: 10.1097/PAS.0000000000000961.

PMID:
28984675
13.

In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium.

Latonen L, Scaravilli M, Gillen A, Hartikainen S, Zhang FP, Ruusuvuori P, Kujala P, Poutanen M, Visakorpi T.

Am J Pathol. 2017 Nov;187(11):2546-2557. doi: 10.1016/j.ajpath.2017.07.012. Epub 2017 Aug 19.

PMID:
28827140
14.

A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL.

Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.

PMID:
28762124
15.

Intestinal epithelial organoids fuse to form self-organizing tubes in floating collagen gels.

Sachs N, Tsukamoto Y, Kujala P, Peters PJ, Clevers H.

Development. 2017 Mar 15;144(6):1107-1112. doi: 10.1242/dev.143933.

16.

Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.

Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A.

J Urol. 2017 Jul;198(1):50-57. doi: 10.1016/j.juro.2017.01.048. Epub 2017 Jan 16.

PMID:
28104375
17.

Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.

Kilpeläinen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A.

Am J Epidemiol. 2016 Nov 15;184(10):720-731. doi: 10.1093/aje/kww084.

PMID:
27777219
18.

Human papillomavirus test with cytology triage in organized screening for cervical cancer.

Veijalainen O, Kares S, Kujala P, Tirkkonen M, Vuento R, Kholová I, Luukkaala T, Osuala V, Mäenpää J.

Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227. doi: 10.1111/aogs.13013.

PMID:
27591407
19.

Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer.

Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu-Lehtinen PI.

Clin Genitourin Cancer. 2017 Feb;15(1):e15-e24. doi: 10.1016/j.clgc.2016.07.008. Epub 2016 Jul 21.

PMID:
27554585
20.

Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus).

Latonen L, Kujala P, Visakorpi T.

Comp Med. 2016;66(4):286-9.

21.

Tumor features and survival after radical prostatectomy among antidiabetic drug users.

Joentausta RM, Kujala PM, Visakorpi T, Tammela TL, Murtola TJ.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):367-373. doi: 10.1038/pcan.2016.32. Epub 2016 Aug 9.

PMID:
27502739
22.

Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.

Pakarainen T, Raitanen J, Talala K, Taari K, Kujala P, Tammela TL, Auvinen A.

Eur Urol. 2016 Sep;70(3):499-505. doi: 10.1016/j.eururo.2016.05.009. Epub 2016 Jun 11.

PMID:
27210461
23.

Risk management model of winter navigation operations.

Valdez Banda OA, Goerlandt F, Kuzmin V, Kujala P, Montewka J.

Mar Pollut Bull. 2016 Jul 15;108(1-2):242-62. doi: 10.1016/j.marpolbul.2016.03.071. Epub 2016 May 18.

24.

Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu-Lehtinen PL.

Clin Genitourin Cancer. 2016 Aug;14(4):e283-9. doi: 10.1016/j.clgc.2015.12.014. Epub 2015 Dec 22.

25.

Statin use and risk of disease recurrence and death after radical prostatectomy.

Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ.

Prostate. 2016 Apr;76(5):469-78. doi: 10.1002/pros.23138. Epub 2015 Dec 22.

PMID:
26689439
26.

A risk analysis of winter navigation in Finnish sea areas.

Valdez Banda OA, Goerlandt F, Montewka J, Kujala P.

Accid Anal Prev. 2015 Jun;79:100-16. doi: 10.1016/j.aap.2015.03.024. Epub 2015 Mar 25.

PMID:
25819212
27.

Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study.

Tolonen TT, Isola J, Kaipia A, Riikonen J, Koivusalo L, Huovinen S, Laurila M, Porre S, Tirkkonen M, Kujala P.

BMC Clin Pathol. 2015 Mar 8;15:4. doi: 10.1186/s12907-015-0001-9. eCollection 2015.

28.

VEGFR3 and CD31 as prognostic factors in renal cell cancer.

Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL.

Anticancer Res. 2015 Feb;35(2):921-7.

PMID:
25667475
29.

The Finnish prostate cancer screening trial: analyses on the screening failures.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

Int J Cancer. 2015 May 15;136(10):2437-43. doi: 10.1002/ijc.29300. Epub 2014 Nov 10.

30.

In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection.

Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, Vries R, Peters PJ, Clevers H.

Gastroenterology. 2015 Jan;148(1):126-136.e6. doi: 10.1053/j.gastro.2014.09.042. Epub 2014 Oct 13.

31.

Family history in the Finnish Prostate Cancer Screening Trial.

Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A.

Int J Cancer. 2015 May 1;136(9):2172-7. doi: 10.1002/ijc.29243. Epub 2014 Oct 10.

32.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

33.

Claudins as prognostic factors for renal cell cancer.

Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, Kellokumpu-Lehtinen PL.

Anticancer Res. 2014 Aug;34(8):4181-7.

PMID:
25075044
34.

Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-γ.

Farin HF, Karthaus WR, Kujala P, Rakhshandehroo M, Schwank G, Vries RG, Kalkhoven E, Nieuwenhuis EE, Clevers H.

J Exp Med. 2014 Jun 30;211(7):1393-405. doi: 10.1084/jem.20130753.

35.

Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology.

Hartmann S, Eray M, Döring C, Lehtinen T, Brunnberg U, Kujala P, Vornanen M, Hansmann ML.

BMC Cancer. 2014 May 13;14:332. doi: 10.1186/1471-2407-14-332.

36.

Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Saarelainen SK, Staff S, Peltonen N, Lehtimäki T, Isola J, Kujala PM, Vuento MH, Mäenpää JU.

Tumour Biol. 2014 May;35(5):4651-7. doi: 10.1007/s13277-014-1609-6. Epub 2014 Jan 14.

PMID:
24420153
37.

Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium.

Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, Mills JC, Clevers H.

Cell. 2013 Oct 10;155(2):357-68. doi: 10.1016/j.cell.2013.09.008.

38.

A probabilistic model estimating oil spill clean-up costs--a case study for the Gulf of Finland.

Montewka J, Weckström M, Kujala P.

Mar Pollut Bull. 2013 Nov 15;76(1-2):61-71. doi: 10.1016/j.marpolbul.2013.09.031. Epub 2013 Oct 7.

39.

Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P; Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Virchows Arch. 2013 Sep;463(3):367-77. doi: 10.1007/s00428-013-1466-5. Epub 2013 Aug 6.

PMID:
23918245
40.

Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis.

Sunela KL, Lehtinen ET, Kataja MJ, Kujala PM, Soimakallio S, Kellokumpu-Lehtinen PL.

BJU Int. 2014 Feb;113(2):228-35. doi: 10.1111/bju.12242. Epub 2013 Jul 26.

41.

Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives.

Staff S, Kujala P, Karhu R, Rökman A, Ilvesaro J, Kares S, Isola J.

J Clin Pathol. 2013 Sep;66(9):807-10. doi: 10.1136/jclinpath-2012-201283. Epub 2013 Jun 8.

PMID:
23750036
42.

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, Kujala PM.

BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.

43.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

PMID:
23479454
44.

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.

Murtola TJ, Kujala PM, Tammela TL.

Prostate. 2013 Jun;73(9):923-31. doi: 10.1002/pros.22638. Epub 2013 Jan 17.

PMID:
23334943
45.

Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1-driven luciferase reporter mouse and human tissue specimens.

Strauss L, Rantakari P, Sjögren K, Salminen A, Lauren E, Kallio J, Damdimopoulou P, Boström M, Boström PJ, Pakarinen P, Zhang F, Kujala P, Ohlsson C, Mäkelä S, Poutanen M.

FASEB J. 2013 Apr;27(4):1342-50. doi: 10.1096/fj.12-219048. Epub 2012 Dec 13.

PMID:
23239821
46.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA.

Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.

47.

Lgr5(+ve) stem/progenitor cells contribute to nephron formation during kidney development.

Barker N, Rookmaaker MB, Kujala P, Ng A, Leushacke M, Snippert H, van de Wetering M, Tan S, Van Es JH, Huch M, Poulsom R, Verhaar MC, Peters PJ, Clevers H.

Cell Rep. 2012 Sep 27;2(3):540-52. doi: 10.1016/j.celrep.2012.08.018. Epub 2012 Sep 20.

48.

Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured "miniguts".

de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N, Martens A, Hofhuis F, DeKoter RP, Peters PJ, Nieuwenhuis E, Clevers H.

Mol Cell Biol. 2012 Sep;32(18):3639-47. doi: 10.1128/MCB.00434-12. Epub 2012 Jul 9.

49.

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

Lehmusvaara S, Erkkilä T, Urbanucci A, Jalava S, Seppälä J, Kaipia A, Kujala P, Lähdesmäki H, Tammela TL, Visakorpi T.

Prostate. 2013 Jan;73(1):101-12. doi: 10.1002/pros.22545. Epub 2012 Jun 5.

PMID:
22674191
50.

Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.

PMID:
22431170

Supplemental Content

Loading ...
Support Center